Prestige BioPharma CEO Sangseok Ko of IDC Purchases Shares on the Open Market

Sangseok Ko, CEO of Prestige BioPharma IDC, has purchased 45,600 shares of Prestige BioPharma on the open market.

According to Prestige BioPharma on September 2, this share acquisition is interpreted as a reflection of the company's confidence in the group's medium- to long-term growth potential, including biosimilar commercialization and innovative new drug research and development.

Previously, Soyeon Park, CEO of Prestige BioPharma, also purchased a total of 213,500 shares of Prestige BioPharma on the open market during July and August, aiming to enhance shareholder trust and demonstrate responsible management.

Prestige BioPharma IDC is a subsidiary responsible for research and development (R&D) for Prestige BioPharma, and leads the group's innovative drug R&D activities. The company has been expanding its research scope to include the discovery and development of antibody drug candidates, next-generation antibody delivery platforms, and diagnostic technologies, focusing on securing future growth engines for the group.

In particular, the company is working on a variety of R&D projects, including ▲ PBP1710, an antibody drug targeting fibrosis and solid tumors ▲ IDC224, a subcutaneous (SC) delivery platform designed to enhance the convenience of antibody therapeutics ▲ and TASATM, a PAUF-based diagnostic technology related to pancreatic cancer. By expanding its research portfolio beyond the development of individual drug candidates to include platforms and diagnostics, the Prestige BioPharma group is strengthening its competitiveness in new drug development.

The Prestige BioPharma group aims to expand revenue through global biosimilar commercialization and foster R&D for innovative new drugs and new platforms as long-term growth drivers. Prestige BioPharma IDC also plans to continue expanding commercialization opportunities by accelerating the development of key pipelines based on its independent R&D capabilities, as well as pursuing joint research and open innovation with external organizations and companies.

CEO Ko stated, "As the group's achievements in biosimilar commercialization and innovative new drug R&D are gradually becoming visible, I decided to purchase these shares with strong confidence in our future growth potential. Prestige BioPharma IDC will further focus on securing competitive new drugs and platform technologies as the core pillar of the group's future growth, and translating them into tangible business outcomes."

This content was produced with the assistance of AI translation services.